(Q24563539)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1 reference

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Federica Di Nicolantonio

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Andrea Sartore-Bianchi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alberto Bardelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Simona Corso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Emanuele Valtorta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Giulia Siravegna

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Giorgia Migliardi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Francesco Galimi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Silvio Marco Veronese

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Giorgio Corti

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Amatu

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Luis Alberto Diaz Jr

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paolo M. Comoglio

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Silvia Giordano

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Salvatore Siena

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

Andrea Bertotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

22

Mark Sausen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

9

Andrea Cassingena

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

25

Livio Trusolino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

20

Marcello Gambacorta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

14

Calogero Lauricella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

4

Sebastijan Hobor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

8

Elisa Scala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

10

Davide Zecchin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Maria Apicella

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Carlo Zanon

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Timothy Perera

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

2 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

658-673

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

2 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Comprehensive molecular characterization of human colon and rectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Development of personalized tumor biomarkers using massively parallel sequencing

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

EGFR antagonists in cancer treatment

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

MET: a promising anticancer therapeutic target

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Targeting MET in cancer: rationale and progress

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

MET signalling: principles and functions in development, organ regeneration and cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Nuclear EGFR contributes to acquired resistance to cetuximab

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Drug development of MET inhibitors: targeting oncogene addiction and expedience

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078408

Genetic heterogeneity and cancer drug resistance

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23729478

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23729478

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23729478

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/2159-8290.CD-12-0558

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23729478%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2 references